Join the Anemia - Sickle Cell group to help and get support from people like you.
Anemia - Sickle Cell News (Page 2)
Related terms: Hemoglobin SS disease (Hb SS), Sickle Cell Anemia, Hemoglobin SS disease, Hb SS, SCD
Exposure to Hydroxyurea Does Not Impact Ovarian Reserve in Sickle Cell
THURSDAY, July 25, 2024 – For girls and young women with sickle cell disease (SCD), exposure to hydroxyurea does not reduce ovarian reserve, according to a study published online July 18 in Blood...
Common Sickle Cell Drug, Hydroxyurea, Won't Harm Female Fertility
MONDAY, July 22, 2024 – A drug called hydroxyurea has long been used to fight sickle cell disease, but some female patients may have shied away from it due to concerns that it could harm future...
Another Study Finds CRISPR Gene Therapy Fights Sickle Cell
TUESDAY, June 18, 2024 – There's more good news in the battle against sickle cell disease, with another trial finding CRISPR gene-editing therapy delivering impressive results for patients. “It’s enc...
Longer Transfer Gap to Adult Care Increases Inpatient Encounters in Sickle Cell Disease
FRIDAY, May 31, 2024 – For young adults (YAs) with sickle cell disease (SCD), a longer transfer gap is associated with increased inpatient encounters and decreased outpatient encounters in adult...
FDA Approves Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 8, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved Lyfgenia (p...
FDA Approves Casgevy (exagamglogene autotemcel) CRISPR/Cas9 Genome-Edited Cell Therapy for the Treatment of Sickle Cell Disease
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Admini...
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE)...
FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accele...
FDA Approves Adakveo (crizanlizumab-tmca) to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease
Basel, November 15, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo (crizanlizumab), previously known as SEG101, to reduce the frequency of v...
FDA Approves Endari (L-glutamine oral powder) for Sickle Cell Disease
July 7, 2017 – The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications...